# US 2022/0033498 A1 · Antibody to fibrosis-related molecule and medical application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033498 A1
- Document ID: US20220033498A1
- Status: Published application
- Kind: A1
- Application number: 17/399,725
- Filed: 2021-08-11
- Published: 2022-02-03
- Earliest claimed: 2016-12-02
- Assignees: The University of Tokyo
- Applicants: The University of Tokyo
- Inventors: Yosuke Kurashima; Hiroshi Kiyono
- Web page: https://patentgrep.com/patent/US20220033498A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2227/105: Murine
- A01K 2267/0368: Animal model for inflammation
- A61K 2039/505: {comprising antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/7052: Fibrosis
- G01N 2800/7095: Inflammation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides an antibody to a fibrosis-related molecule and medical application thereof. The antibody of the present invention is an antibody that binds to CHL1 protein and an antibody that neutralizes the binding of the CHL1 protein to a fibroblast.

## Claims

### Claim 1

A method for analyzing the presence or absence of inflammation in a tissue in a subject, comprising determining the presence of secreted CHL1 protein in the tissue, a body fluid, or excrement obtained from the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the presence or absence of the CHL1 protein is detected using an antibody that binds to secreted CHL1 protein, or an antigen-binding fragment thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the presence or absence of the CHL1 protein is detected using an antibody or an antigen-binding fragment thereof that binds to secreted CHL1 protein, wherein the antibody or the fragment has a heavy chain variable region having heavy chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 1, heavy chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 2 and heavy chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 3, and a light chain variable region having light chain CDR1 having the amino acid sequence set forth in SEQ ID NO: 5, light chain CDR2 having the amino acid sequence set forth in SEQ ID NO: 6 and light chain CDR3 having the amino acid sequence set forth in SEQ ID NO: 7.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the excrement is a feces and the tissue is intestine.

### Claim 5

A method of detecting inflammation in an intestine in a subject, comprising detecting CHL1 protein in a feces obtained from the subject, and determining that inflammation is detected in the intestine in a subject, based on the presence of CHL1 protein.

### Claim 6 (depends on 2)

A method of claim 2, further comprising administering to the subject an antibody that binds to secreted CHL1 protein and can neutralizes the binding of the secreted CHL1 protein to a non-immune and non-epithelial non-hemocyte cell of the lamina propria and a submucosal layer.

### Claim 7 (depends on 3)

A method of claim 3, further comprising administering to the subject an antibody that binds to secreted CHL1 protein and can neutralizes the binding of the secreted CHL1 protein to a non-immune and non-epithelial non-hemocyte cell of the lamina propria and a submucosal layer.

### Claim 8 (depends on 5)

A method of claim 5, further comprising administering to the subject an antibody that binds to secreted CHL1 protein and can neutralizes the binding of the secreted CHL1 protein to a non-immune and non-epithelial non-hemocyte cell of the lamina propria and a submucosal layer.
